Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors
K Takada, Y Yoneshima, K Tanaka, I Okamoto… - Journal of Cancer …, 2020 - Springer
Purpose The aim of this study was to elucidate the clinical impact of skeletal muscle area
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors
K Takada, Y Yoneshima, K Tanaka… - Journal of cancer …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose The aim of this study was to elucidate the clinical impact of skeletal muscle area
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors
K Takada, Y Yoneshima, K Tanaka… - Journal of Cancer …, 2020 - kyushu-u.elsevierpure.com
Purpose: The aim of this study was to elucidate the clinical impact of skeletal muscle area
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors
K Takada, Y Yoneshima, K Tanaka… - Journal of Cancer …, 2020 - kyushu-u.pure.elsevier.com
Purpose: The aim of this study was to elucidate the clinical impact of skeletal muscle area
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
[引用][C] Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors
K Takada, Y Yoneshima, K Tanaka, I Okamoto… - Journal of Cancer …, 2020 - cir.nii.ac.jp
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with
anti-PD-1 inhibitors | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
anti-PD-1 inhibitors | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.
K Takada, Y Yoneshima, K Tanaka… - Journal of Cancer …, 2020 - europepmc.org
Purpose The aim of this study was to elucidate the clinical impact of skeletal muscle area
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors
T Kazuki, Y Yasuto, K Tanaka, O Isamu… - Journal of Cancer …, 2020 - search.proquest.com
Purpose The aim of this study was to elucidate the clinical impact of skeletal muscle area
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.
K Takada, Y Yoneshima, K Tanaka… - Journal of Cancer …, 2020 - search.ebscohost.com
Purpose: The aim of this study was to elucidate the clinical impact of skeletal muscle area
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …
(SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed …